hVIVO (LON:HVO) Trading 23% Higher - Still a Buy?

hVIVO plc (LON:HVO - Get Free Report) shares were up 23% during trading on Monday . The stock traded as high as GBX 11 ($0.15) and last traded at GBX 10.70 ($0.15). Approximately 24,253,932 shares changed hands during mid-day trading, an increase of 569% from the average daily volume of 3,624,890 shares. The stock had previously closed at GBX 8.70 ($0.12).

Analysts Set New Price Targets

Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a research note on Friday, May 30th.

hVIVO Stock Performance

The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86. The stock has a fifty day simple moving average of GBX 15.92 and a 200 day simple moving average of GBX 17.70. The firm has a market capitalization of £73.59 million, a P/E ratio of 4.29 and a beta of 0.97.

hVIVO (LON:HVO - Get Free Report) last released its earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. As a group, research analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

Insider Buying and Selling at hVIVO

In other news, insider Yamin Mo' Khan sold 3,062,246 shares of the firm's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total transaction of £520,581.82 ($705,491.02). 14.03% of the stock is owned by corporate insiders.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.